angiotensin ii has been researched along with Dyslipidemia in 14 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (35.71) | 29.6817 |
| 2010's | 7 (50.00) | 24.3611 |
| 2020's | 2 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Barthelemy, J; Bogard, G; Briand, F; Chabrat, A; Deruyter, L; Domenig, O; Heumel, S; Hoffmann, E; Infanti, F; Machelart, A; Nogueiras, R; Pinet, F; Prévot, V; Richard, V; Robil, C; Sencio, V; Sulpice, T; Trottein, F; Wolowczuk, I | 1 |
| Alirezaei, A; Argani, H; Ghorbanihaghjo, A; Jabarpour, M; Panah, F; Ranjbarzadhag, M; Rashtchizadeh, N; Sanajou, D | 1 |
| Adler, GK; Baudrand, R; Easly, RM; Haas, AV; Hopkins, PN; Jeunemaitre, X; Murray, GR; Pojoga, LH; Rosner, B; Touyz, RM; Williams, GH; Williams, JS | 1 |
| Abbott, GW; Anand, M; Christini, DJ; Hu, Z; Kant, R; King, EC; Krogh-Madsen, T | 1 |
| da Silva Viegas, KA; de Marco Ornelas, E; de Souza, RR; Fonseca, FL; Lacchini, S; Maifrino, LB; Marchon, C | 1 |
| Chen, PP; Hu, ZB; Liu, BC; Liu, L; Lu, J; Ma, KL; Ruan, XZ; Wang, GH; Wen, Y; Wu, Y; Zhang, Y | 1 |
| Côco, H; de Oliveira, AM; Franco, JJ; Gomes, MS; Hipólito, UV; Marchi, KC; Pereira, PC; Pernomian, L; Tirapelli, CR; Uyemura, SA | 1 |
| Anandan, SK; Chen, D; Cheng, Y; Gless, R; Mehra, U; Vincelette, J; Wang, YX; Webb, HK; Zhang, LN | 1 |
| Sharma, PL; Singh, K; Singh, T | 1 |
| Burghi, V; Carranza, A; Dominici, FP; Giani, JF; Mayer, MA; Muñoz, MC; Taira, CA | 1 |
| Howes, LG | 1 |
| Prabhakar, S; Rosario, RF | 1 |
| Kawecka-Jaszcz, K; Pośnik-Urbańska, A | 1 |
| Miller, AG; Wilkinson-Berka, JL | 1 |
5 review(s) available for angiotensin ii and Dyslipidemia
| Article | Year |
|---|---|
The impact of dyslipidemia and oxidative stress on vasoactive mediators in patients with renal dysfunction.
Topics: Angiotensin II; Dyslipidemias; Endothelin-1; Humans; Nitric Oxide; Oxidative Stress; Proprotein Convertase 9; Renal Insufficiency, Chronic | 2019 |
The effects of lipid-lowering drug therapy on cardiovascular responsiveness in type 2 diabetic patients.
Topics: Angiotensin II; Blood Pressure; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dyslipidemias; Endothelium, Vascular; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Infusions, Intravenous; Lipoproteins; Norepinephrine; Vasodilation | 2006 |
Lipids and diabetic nephropathy.
Topics: Angiotensin II; Animals; Apolipoproteins E; Diabetic Nephropathies; Disease Models, Animal; Disease Progression; Dyslipidemias; Glycation End Products, Advanced; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Polymorphism, Genetic; Safety | 2006 |
[Hypertension in postmenopausal women --selected pathomechanisms].
Topics: Age Factors; Aldosterone; Angiotensin II; Blood Pressure; Body Mass Index; Dyslipidemias; Estrogen Replacement Therapy; Estrogens; Female; Humans; Hypertension; Middle Aged; Obesity; Postmenopause; Renin-Angiotensin System | 2006 |
Update on the treatment of diabetic retinopathy.
Topics: Adrenal Cortex Hormones; Aldehyde Reductase; Angiotensin II; Antihypertensive Agents; Blood Glucose; Clofibric Acid; Diabetes Mellitus, Type 2; Diabetic Retinopathy; Dyslipidemias; Enzyme Inhibitors; Glycation End Products, Advanced; Human Growth Hormone; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Insulin; Laser Coagulation; Protein Kinase C; Vascular Endothelial Growth Factor A; Vitamin E | 2008 |
9 other study(ies) available for angiotensin ii and Dyslipidemia
| Article | Year |
|---|---|
Diet-Induced Obesity and NASH Impair Disease Recovery in SARS-CoV-2-Infected Golden Hamsters.
Topics: Angiotensin II; Angiotensin-Converting Enzyme 2; Animals; COVID-19; Cricetinae; Cytokines; Diet; Disease Models, Animal; Dyslipidemias; Humans; Inflammation; Mesocricetus; Non-alcoholic Fatty Liver Disease; Obesity; SARS-CoV-2 | 2022 |
Interplay Between Statins, Cav1 (Caveolin-1), and Aldosterone.
Topics: Adrenal Glands; Aldosterone; Angiotensin II; Caveolin 1; Cholesterol; Correlation of Data; Dyslipidemias; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Male; Pharmacogenomic Testing; Pharmacogenomic Variants; Polymorphism, Single Nucleotide | 2020 |
Kcne2 deletion creates a multisystem syndrome predisposing to sudden cardiac death.
Topics: Anemia; Angiotensin II; Angiotensinogen; Animals; Arrhythmias, Cardiac; Death, Sudden, Cardiac; Diabetes Mellitus; Dyslipidemias; Gene Regulatory Networks; Genotype; Heterozygote; Hyperkalemia; Ischemia; Long QT Syndrome; Mice; Mice, Knockout; Potassium Channels, Voltage-Gated | 2014 |
Effects of moderate exercise on the biochemical, physiological, morphological and functional parameters of the aorta in the presence of estrogen deprivation and dyslipidemia: an experimental model.
Topics: Angiotensin II; Animals; Aorta; Blood Pressure; Body Weight; Cholesterol; Dyslipidemias; Elastic Modulus; Estrogens; Female; Heart Rate; Mice; Mice, Inbred C57BL; Mice, Knockout; Models, Animal; Ovariectomy; Peptidyl-Dipeptidase A; Physical Conditioning, Animal; Tensile Strength; Triglycerides | 2015 |
Lipid disorder and intrahepatic renin-angiotensin system activation synergistically contribute to non-alcoholic fatty liver disease.
Topics: Angiotensin II; Animals; Benzimidazoles; Benzoates; Cholesterol; Diet, High-Fat; Dyslipidemias; Extracellular Matrix; Hep G2 Cells; Humans; Intracellular Signaling Peptides and Proteins; Lipid Metabolism; Male; Membrane Proteins; Mice; Mice, Inbred C57BL; Mice, Knockout; Non-alcoholic Fatty Liver Disease; Receptor, Angiotensin, Type 1; Receptors, LDL; Renin-Angiotensin System; Signal Transduction; Sterol Regulatory Element Binding Protein 2; Telmisartan | 2016 |
Auto-inhibitory regulation of angiotensin II functionality in hamster aorta during the early phases of dyslipidemia.
Topics: Angiotensin II; Animals; Aorta; Catalase; Cricetinae; Diet, High-Fat; Dyslipidemias; Hydrogen Peroxide; Male; NADPH Oxidases; Nitric Oxide; Oxidative Stress; Reactive Oxygen Species; Renin-Angiotensin System; Superoxide Dismutase; Time Factors; Vasoconstriction | 2016 |
Inhibition of soluble epoxide hydrolase attenuated atherosclerosis, abdominal aortic aneurysm formation, and dyslipidemia.
Topics: Administration, Oral; Angiotensin II; Animals; Aortic Aneurysm, Abdominal; Apolipoproteins E; Atherosclerosis; Biological Availability; Carotid Arteries; Cholesterol; Disease Models, Animal; Down-Regulation; Dyslipidemias; Enzyme Inhibitors; Epoxide Hydrolases; Inflammation Mediators; Intercellular Adhesion Molecule-1; Interleukin-1alpha; Interleukin-6; Interleukin-8; Ligation; Male; Mice; Mice, Knockout; Vascular Cell Adhesion Molecule-1 | 2009 |
Beneficial effects of angiotensin (1-7) in diabetic rats with cardiomyopathy.
Topics: Angiotensin I; Angiotensin II; Animals; Blood Glucose; Collagen; Diabetes Mellitus, Experimental; Diabetic Cardiomyopathies; Dyslipidemias; Fibrosis; Heart Ventricles; Hypertrophy, Left Ventricular; Lipids; Nitrates; Nitrites; Peptide Fragments; Proto-Oncogene Mas; Proto-Oncogene Proteins; Rats; Rats, Wistar; Receptors, G-Protein-Coupled; Time Factors; Ventricular Function, Left; Ventricular Pressure | 2011 |
The Mas receptor mediates modulation of insulin signaling by angiotensin-(1-7).
Topics: Adipose Tissue; Angiotensin I; Angiotensin II; Animals; Blood Pressure; Dyslipidemias; Fructose; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; GTPase-Activating Proteins; Hypertension; Insulin; Insulin Resistance; Liver; Male; Muscle, Skeletal; Peptide Fragments; Phosphorylation; Proto-Oncogene Mas; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Rats; Rats, Sprague-Dawley; Receptors, G-Protein-Coupled; Signal Transduction | 2012 |